Overview
Chai Discovery leverages artificial intelligence to engineer superior molecules, specifically focusing on drug-like antibody design. Their platform, Chai-2, moves beyond simple binding affinity, aiming to design antibodies closer to becoming real therapeutics. The AI architecture likely involves deep learning models trained on extensive datasets of antibody sequences, structures, and binding affinities. This allows for de novo design against challenging targets with atomic precision. The value proposition centers around accelerating the drug discovery process, reducing the reliance on traditional, time-consuming methods. Use cases include designing antibodies for novel therapeutic targets, optimizing existing antibody candidates for improved efficacy and developability, and generating diverse antibody libraries for screening.